Clinical Trial Update: Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial of Lutetium Lu-177 JH020002 Injection for advanced prostate cancer is currently recruiting, sponsored by Bivision Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Lutetium Lu-177 JH020002 Injection (Lutetium-177 JH020002)

Snippet

Sponsor: Bivision Pharmaceuticals, Inc. | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: RECRUITING